Hydroxyethyl starch: The effect of molecular weight and degree of substitution on intravascular retention in vivo

Takashi Hitosugi, Toshiyuki Saito, Sono Suzuki, Ieko Kubota, Emi Shoda, Toru Shimizu, Yoshiyuki Oi

研究成果: ジャーナルへの寄稿記事

7 引用 (Scopus)

抄録

BACKGROUND: Hydroxyethyl starch (HES) solution is characterized by its mean molecular weight (MW), concentration, and degree of substitution (DS). This character varies worldwide. METHODS: After binding fluorescein-isothiocyanate (FITC-HES), we evaluated the retention rate of three types of 6% HES in the A2 and V2 blood vessels of rat cremaster muscles using intravital microscopy in a mild hemorrhage model (10% of total blood volume). After blood withdrawal, we infused three types of FITC-HES: HES-A (MW 150-200 kDa, DS 0.6-0.68), HES-B (MW 175-225 kDa, DS 0.45-0.55), or HES-C (MW 550-850 kDa, DS 0.7-0.8) before determining the FITC-HES retention rate in the intravital microscope. RESULTS: For V2, the FITC-HES retention rates 120 min after the start of the infusion were 27% ± 7.2% of baseline values (HES-A), 65% ± 9.1% (HES-B), and 86% ± 9.6% (HES-C); for A2 they were 27% ± 6.6%, 73% ± 10.2%, and 89% ± 8.7%, respectively. HES-B and HES-C were retained in the vessels longer than HES-A (P = 0.028 for V2, P = 0.038 for A2 between HES-B and HES-A; P = 0.022 for V2, P = 0.037 for A2 between HES-C and HES-A). There was no difference in the rate of disappearance from the vessels between HES-B and HES-C. CONCLUSIONS: HES-B and HES-C are equally retained in the blood vessels. Middle-sized HES-B with low DS and middle substitution pattern stayed in the blood vessels as long as the large-sized HES. HES solutions of varying characters should be examined to optimize HES infusion.

元の言語英語
ページ(範囲)724-728
ページ数5
ジャーナルAnesthesia and Analgesia
105
発行部数3
DOI
出版物ステータス出版済み - 9 1 2007
外部発表Yes

Fingerprint

Starch
Molecular Weight
Fluorescein-5-isothiocyanate
varespladib methyl
Blood Vessels
Abdominal Muscles

All Science Journal Classification (ASJC) codes

  • Anesthesiology and Pain Medicine

これを引用

Hydroxyethyl starch : The effect of molecular weight and degree of substitution on intravascular retention in vivo. / Hitosugi, Takashi; Saito, Toshiyuki; Suzuki, Sono; Kubota, Ieko; Shoda, Emi; Shimizu, Toru; Oi, Yoshiyuki.

:: Anesthesia and Analgesia, 巻 105, 番号 3, 01.09.2007, p. 724-728.

研究成果: ジャーナルへの寄稿記事

Hitosugi, Takashi ; Saito, Toshiyuki ; Suzuki, Sono ; Kubota, Ieko ; Shoda, Emi ; Shimizu, Toru ; Oi, Yoshiyuki. / Hydroxyethyl starch : The effect of molecular weight and degree of substitution on intravascular retention in vivo. :: Anesthesia and Analgesia. 2007 ; 巻 105, 番号 3. pp. 724-728.
@article{8d6d7a4058bf413e8782998e9caea337,
title = "Hydroxyethyl starch: The effect of molecular weight and degree of substitution on intravascular retention in vivo",
abstract = "BACKGROUND: Hydroxyethyl starch (HES) solution is characterized by its mean molecular weight (MW), concentration, and degree of substitution (DS). This character varies worldwide. METHODS: After binding fluorescein-isothiocyanate (FITC-HES), we evaluated the retention rate of three types of 6{\%} HES in the A2 and V2 blood vessels of rat cremaster muscles using intravital microscopy in a mild hemorrhage model (10{\%} of total blood volume). After blood withdrawal, we infused three types of FITC-HES: HES-A (MW 150-200 kDa, DS 0.6-0.68), HES-B (MW 175-225 kDa, DS 0.45-0.55), or HES-C (MW 550-850 kDa, DS 0.7-0.8) before determining the FITC-HES retention rate in the intravital microscope. RESULTS: For V2, the FITC-HES retention rates 120 min after the start of the infusion were 27{\%} ± 7.2{\%} of baseline values (HES-A), 65{\%} ± 9.1{\%} (HES-B), and 86{\%} ± 9.6{\%} (HES-C); for A2 they were 27{\%} ± 6.6{\%}, 73{\%} ± 10.2{\%}, and 89{\%} ± 8.7{\%}, respectively. HES-B and HES-C were retained in the vessels longer than HES-A (P = 0.028 for V2, P = 0.038 for A2 between HES-B and HES-A; P = 0.022 for V2, P = 0.037 for A2 between HES-C and HES-A). There was no difference in the rate of disappearance from the vessels between HES-B and HES-C. CONCLUSIONS: HES-B and HES-C are equally retained in the blood vessels. Middle-sized HES-B with low DS and middle substitution pattern stayed in the blood vessels as long as the large-sized HES. HES solutions of varying characters should be examined to optimize HES infusion.",
author = "Takashi Hitosugi and Toshiyuki Saito and Sono Suzuki and Ieko Kubota and Emi Shoda and Toru Shimizu and Yoshiyuki Oi",
year = "2007",
month = "9",
day = "1",
doi = "10.1213/01.ane.0000275198.84094.ad",
language = "English",
volume = "105",
pages = "724--728",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Hydroxyethyl starch

T2 - The effect of molecular weight and degree of substitution on intravascular retention in vivo

AU - Hitosugi, Takashi

AU - Saito, Toshiyuki

AU - Suzuki, Sono

AU - Kubota, Ieko

AU - Shoda, Emi

AU - Shimizu, Toru

AU - Oi, Yoshiyuki

PY - 2007/9/1

Y1 - 2007/9/1

N2 - BACKGROUND: Hydroxyethyl starch (HES) solution is characterized by its mean molecular weight (MW), concentration, and degree of substitution (DS). This character varies worldwide. METHODS: After binding fluorescein-isothiocyanate (FITC-HES), we evaluated the retention rate of three types of 6% HES in the A2 and V2 blood vessels of rat cremaster muscles using intravital microscopy in a mild hemorrhage model (10% of total blood volume). After blood withdrawal, we infused three types of FITC-HES: HES-A (MW 150-200 kDa, DS 0.6-0.68), HES-B (MW 175-225 kDa, DS 0.45-0.55), or HES-C (MW 550-850 kDa, DS 0.7-0.8) before determining the FITC-HES retention rate in the intravital microscope. RESULTS: For V2, the FITC-HES retention rates 120 min after the start of the infusion were 27% ± 7.2% of baseline values (HES-A), 65% ± 9.1% (HES-B), and 86% ± 9.6% (HES-C); for A2 they were 27% ± 6.6%, 73% ± 10.2%, and 89% ± 8.7%, respectively. HES-B and HES-C were retained in the vessels longer than HES-A (P = 0.028 for V2, P = 0.038 for A2 between HES-B and HES-A; P = 0.022 for V2, P = 0.037 for A2 between HES-C and HES-A). There was no difference in the rate of disappearance from the vessels between HES-B and HES-C. CONCLUSIONS: HES-B and HES-C are equally retained in the blood vessels. Middle-sized HES-B with low DS and middle substitution pattern stayed in the blood vessels as long as the large-sized HES. HES solutions of varying characters should be examined to optimize HES infusion.

AB - BACKGROUND: Hydroxyethyl starch (HES) solution is characterized by its mean molecular weight (MW), concentration, and degree of substitution (DS). This character varies worldwide. METHODS: After binding fluorescein-isothiocyanate (FITC-HES), we evaluated the retention rate of three types of 6% HES in the A2 and V2 blood vessels of rat cremaster muscles using intravital microscopy in a mild hemorrhage model (10% of total blood volume). After blood withdrawal, we infused three types of FITC-HES: HES-A (MW 150-200 kDa, DS 0.6-0.68), HES-B (MW 175-225 kDa, DS 0.45-0.55), or HES-C (MW 550-850 kDa, DS 0.7-0.8) before determining the FITC-HES retention rate in the intravital microscope. RESULTS: For V2, the FITC-HES retention rates 120 min after the start of the infusion were 27% ± 7.2% of baseline values (HES-A), 65% ± 9.1% (HES-B), and 86% ± 9.6% (HES-C); for A2 they were 27% ± 6.6%, 73% ± 10.2%, and 89% ± 8.7%, respectively. HES-B and HES-C were retained in the vessels longer than HES-A (P = 0.028 for V2, P = 0.038 for A2 between HES-B and HES-A; P = 0.022 for V2, P = 0.037 for A2 between HES-C and HES-A). There was no difference in the rate of disappearance from the vessels between HES-B and HES-C. CONCLUSIONS: HES-B and HES-C are equally retained in the blood vessels. Middle-sized HES-B with low DS and middle substitution pattern stayed in the blood vessels as long as the large-sized HES. HES solutions of varying characters should be examined to optimize HES infusion.

UR - http://www.scopus.com/inward/record.url?scp=34548140151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548140151&partnerID=8YFLogxK

U2 - 10.1213/01.ane.0000275198.84094.ad

DO - 10.1213/01.ane.0000275198.84094.ad

M3 - Article

C2 - 17717230

AN - SCOPUS:34548140151

VL - 105

SP - 724

EP - 728

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 3

ER -